Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study

Table 3 Area under the receiver operating characteristic curve and optimal value to discriminate subjects with Alzheimer’s disease from those without ^a

CSF biomarkers, pg/ml		AUC (SE)	Optimal value	Sensitivity	Specificity	Youden index
Overall
	Total tau	0.87 (0.02)	330	0.84	0.81	0.65
	p-tau181	0.90 (0.02)	62	0.79	0.91	0.70
	Aβ42	0.81 (0.02)	752	0.78	0.79	0.57
	Aβ 42/40	0.81 (0.02)	0.055	0.73	0.78	0.51
Center 1
	Total tau	0.96 (0.01)	300	0.95	0.96	0.91
	pTau-181	0.95 (0.02)	58	0.86	0.91	0.77
	Aβ42	0.81 (0.05)	814	0.84	0.80	0.64
	Aβ 42/40	0.93 (0.03)	0.065	0.89	0.84	0.73
Center 2
	Total tau	0.91 (0.03)	389	0.86	0.82	0.68
	p-tau181	0.91 (0.03)	64	0.85	0.86	0.71
	Aβ42	0.82 (0.04)	836	0.90	0.71	0.61
	Aβ 42/40	0.87 (0.03)	0.082	0.90	0.67	0.57
Center 3
	Total tau	0.77 (0.04)	343	0.74	0.77	0.51
	p-tau181	0.84 (0.04)	62	0.72	0.92	0.64
	Aβ42	0.74 (0.05)	737	0.70	0.80	0.50
	Aβ 42/40	0.75 (0.04)	0.050	0.64	0.79	0.43

^aAβ, Amyloid-beta; AUC, Area under the receiver operating characteristic curve; CSF, Cerebrospinal fluid; p-tau181, tau phosphorylated at threonine 181; SE, Standard error.

ISSN: 1758-9193